Literature DB >> 9933171

Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence.

K M George1, D Chatterjee, G Gunawardana, D Welty, J Hayman, R Lee, P L Small.   

Abstract

Mycobacterium ulcerans is the causative agent of Buruli ulcer, a severe human skin disease that occurs primarily in Africa and Australia. Infection with M. ulcerans results in persistent severe necrosis without an acute inflammatory response. The presence of histopathological changes distant from the site of infection suggested that pathogenesis might be toxin mediated. A polyketide-derived macrolide designated mycolactone was isolated that causes cytopathicity and cell cycle arrest in cultured L929 murine fibroblasts. Intradermal inoculation of purified toxin into guinea pigs produced a lesion similar to that of Buruli ulcer in humans. This toxin may represent one of a family of virulence factors associated with pathology in mycobacterial diseases such as leprosy and tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933171     DOI: 10.1126/science.283.5403.854

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  240 in total

1.  Structural and functional cellular changes induced by Burkholderia pseudomallei rhamnolipid.

Authors:  S Häussler; M Rohde; N von Neuhoff; M Nimtz; I Steinmetz
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

2.  Buruli ulcer: the third most common mycobacterial infection.

Authors:  Erica Weir
Journal:  CMAJ       Date:  2002-06-25       Impact factor: 8.262

3.  Mycobacterium ulcerans causes minimal pathogenesis and colonization in medaka (Oryzias latipes): an experimental fish model of disease transmission.

Authors:  Lydia Mosi; Nadine K Mutoji; Fritz A Basile; Robert Donnell; Kathrine L Jackson; Thomas Spangenberg; Yoshito Kishi; Don G Ennis; Pamela L C Small
Journal:  Microbes Infect       Date:  2012-03-14       Impact factor: 2.700

4.  Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.

Authors:  Tianyu Zhang; Si-Yang Li; Paul J Converse; Deepak V Almeida; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 5.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

6.  CHEMICAL AND MINERALOGICAL CHARACTERISTICS OF FRENCH GREEN CLAYS USED FOR HEALING.

Authors:  Lynda B Williams; Shelley E Haydel; Rossman F Giese; Dennis D Eberl
Journal:  Clays Clay Miner       Date:  2008-08       Impact factor: 1.609

7.  Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease.

Authors:  F Portaels; J Aguiar; M Debacker; A Guédénon; C Steunou; C Zinsou; W M Meyers
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Analysis of Mycobacterium species for the presence of a macrolide toxin, mycolactone.

Authors:  Alexa K Daniel; Richard E Lee; Francoise Portaels; P L C Small
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.

Authors:  A Bentoucha; J Robert; H Dega; N Lounis; V Jarlier; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR.

Authors:  Gustavo P Riboldi; Rachael Zigweid; Peter J Myler; Stephen J Mayclin; Rafael M Couñago; Bart L Staker
Journal:  RSC Med Chem       Date:  2020-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.